Divestment

Tigenix (Cellerix)

Tigenix (Cellerix) developed stem cell therapies for autoimmune diseases.

Responsible partner
Responsible partner

Key Facts

Sector: Life Sciences
Country: Belgium
Fund: LSP 3
Entry: 2007
Exit: 2013

Responsible Partner

Joachim Rothe

Joachim Rothe

Partner

News

April 7, 2026
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

Do You Want to Know More?

We are eager to explore how we can achieve great things together.